TLR3Δ64 Variant Suppressing TLR3 Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with Toll-like receptor 3 (TLR3) activity, such as inflammatory and autoimmune diseases, are limited, and there is a need to suppress TLR3 activity to manage these conditions effectively.
Innovation Solution
Development of a TLR3 variant, specifically TLR3Δ64, which lacks amino acid residues 289-352, interfering with TLR3 translocation and activity, thereby suppressing TLR3 activity in subjects needing treatment for inflammatory, necrotic, infectious, cardiovascular, and other diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR3 activity is suppressed to treat inflammatory and autoimmune diseases, then therapeutic benefit is improved, but the complexity of developing and validating specific TLR3 inhibitors increases
Solution Approach 1:
The patent extracts and removes a specific functional domain (amino acid residues 289-352) from the TLR3 protein to create a truncated variant (TLR3Δ64) that lacks ligand binding capability. This extraction approach simplifies the therapeutic mechanism by eliminating the problematic functional region while retaining the receptor's structural framework, thereby reducing development complexity compared to creating entirely new inhibitory molecules.
Solution Approach 2:
The patent modifies the TLR3 protein structure by changing the amino acid sequence parameters - specifically deleting 64 amino acids (residues 289-352) from the extracellular domain. This parameter change transforms the wild-type TLR3 into a functional variant that cannot bind ligands, providing a straightforward mechanism for suppressing TLR3 activity without requiring complex drug delivery systems or multiple therapeutic components.
2Measurement precision
If a TLR3 variant lacking amino acid residues 289-352 is used to suppress TLR3 activity, then specificity for TLR3 is improved, but the difficulty of producing and purifying the variant increases
Solution Approach 1:
The patent segments the TLR3 protein into functional domains, specifically removing the ligand binding domain (residues 289-352) while retaining the transmembrane and cytoplasmic domains. This segmentation allows for targeted modification of only the problematic region, making the variant easier to produce and purify compared to creating completely novel proteins, as the truncated TLR3 variant can still be expressed using standard recombinant protein production systems.
3Object-generated harmful factors
If TLR3 translocation is interfered with to suppress activity, then reduction of pro-inflammatory cytokine secretion is improved, but the complexity of mechanism validation increases
Solution Approach 1:
The patent converts the harmful ligand binding function of TLR3 into a benefit by creating a variant that cannot bind ligands. The truncated TLR3 variant (TLR3Δ64) retains the receptor's structural framework and can still be expressed on cell surfaces, but the deleted amino acid residues 289-352 eliminate ligand binding capability. This conversion of a functional domain into a non-functional element provides a straightforward mechanism for suppressing pro-inflammatory cytokine secretion without requiring complex validation approaches, as the lack of ligand binding can be directly measured and correlated with reduced signaling.
Data Source
Figure 1
Figure 2
Figure 3A~3F
AI summary
Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed.